Protective effect of chymase inhibitor on renal function in diabetic hamsters

ZHANG Meng-shu, LIU Jin-lei, LIU Xue-zheng,ZHOU Hong-li, ZHANG Rong-ming

Chinese Journal of Clinical Anatomy ›› 2016, Vol. 34 ›› Issue (6) : 661-667.

Chinese Journal of Clinical Anatomy ›› 2016, Vol. 34 ›› Issue (6) : 661-667. DOI: 10.13418/j.issn.1001-165x.2016.06.013

Protective effect of chymase inhibitor on renal function in diabetic hamsters

  • ZHANG Meng-shu1, LIU Jin-lei2, LIU Xue-zheng3,ZHOU Hong-li4, ZHANG Rong-ming1
Author information +
History +

Abstract

Objective To observe the protective effect of chymotrypsin inhibitors on diabetic hamster kidney, and to explore  mechanism underlying the protection. Methods Diabetic hamsters was established by intraperitoneal injection of STZ. The animal chymotrypsin, RAS components: ACE, renin, ANG-I, ANG-II; oxidative stress levels: 8-OhdG, NOX-4, p22phox, and the expression of TGF-β1 were determined by molecular biologic techniques, immunohistochemistry, western blotting technique. Results Chymotrypsin inhibitors inhibited the increase of ANG-II in diabetic hamster kidney, but significantly reduced the level of 8-OHdG secretion. NOX-4 and p22phox staining indicated significantly increased products of oxidation products in diabetic glomerulus and tubules, which could be significantly inhibited by chymotrypsin inhibitors (P<0.01). Western blot confirmed that the level of NOX-4 and p22phox increased in the diabetic group than in the control group, and chymotrypsin inhibitor could significantly reduce its expression. Glomerular TGF-β1 expression in the diabetic group was higher than that in the control group, and the chymotrypsin inhibitor therapy could significantly reduce the levels of TGF-β1. Conclusions Chymotrypsin inhibitors can protect diabetic hamster kidney function, and the underlying  mechanism is through reducing renal ANG-II levels and oxidative stress levels to protect diabetic kidney damage.

Key words

Chymase inhibitor / Oxidative stress / Kidney / Diabetic hamsters

Cite this article

Download Citations
ZHANG Meng-shu, LIU Jin-lei, LIU Xue-zheng,ZHOU Hong-li, ZHANG Rong-ming. Protective effect of chymase inhibitor on renal function in diabetic hamsters[J]. Chinese Journal of Clinical Anatomy. 2016, 34(6): 661-667 https://doi.org/10.13418/j.issn.1001-165x.2016.06.013

References

[1] Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes[J]. J Hypertens, 2006, 24(1): 11-25.
[2] Mahmoud F, Al-Ozairi E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes[J]. Disease Markers, 2013, 35(4): 235-241.
[3] Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells[J]. Circ Res, 2007, 101(5): 455-464.
[4]  Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition[J]. Cardiovasc Res, 2004, 61(4): 653-662.
[5] Huang XR, ChenWY, Truong LD, et al. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular diseas[J]. J Am Soc Nephrol, 2003, 14(7): 1738-1747.
[6]  Cristovam PC, Arnoni CP, de Andrade MC, et al. ACE-dependent and chymase- dependent angiotensin II generation in normal and glucose- stimulated human mesangial cells[J]. Exp Biol Med, 2008, 233(8): 1035-1043.
[7] Lee EJ, Chen HY, Lee MY, et al. Cinnamophilin reduces oxidative damage and protects against transient focal cerebral ischemia in mice[J]. Free Radic Biol Med, 2005, 39(4): 495-510.
[8]  Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes[J]. Kidney Int, 2007, 71(10): 1019-1027.
[9] Gumprecht J, Zychma M, Grzeszczak W, et al. Angiotensin I-converting enzyme and chymase gene polymorphisms - relationship to left ventricular mass in type 2 diabetes patients[J]. Med Sci Monit, 2002, 8(8): CR603-CR606.
[10]Rong JM, Ji HZ, Wu XW, et al. Increased expression of chymase in inflammatory polyps in elderly patients with functional bowel disorder[J]. Exp Ther Med, 2014, 7(2):371-374.
[11]Wang Y, Gu Y, Lewis DF, et al. Elevated plasma chymotrypsin-like protease (chymase) activity in women with preeclampsia[J]. Hypertens Pregnancy, 2010, 29(3): 253-261.
[12]D'Orléans-Juste P, Houde M, Rae GA, et al. Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies[J]. Vascul Pharmacol, 2008, 49(2-3): 51-62.
[13]Miyazaki M, Takai S, Jin D, et al. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models[J]. Pharmacol Ther, 2006, 112(3): 668-676.
[14]Gorin Y, Block K, Hernandez J, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and ?bronectin expression in the diabetic kidney[J]. J Biol Chem, 2005, 280(47): 39616-39626.

Accesses

Citation

Detail

Sections
Recommended

/